A Closer Look: ThinkMyco pushes the button on magic mushroom market


Psilocybin and other psychedelics are forcing their way out of prohibition as potentially viable treatments for not only depression and anxiety but also Alzheimer’s and other neurodegenerative diseases plaguing millions in North America alone. In the end, psilocybin solutions address a $300 billion dollar psychotherapy and wellness global market.

Shroom Stocks’ own Ethan Reyes spoke with Nikita Alexandrov, CTO of ThinkMyco, to get a good look at the company, the sector and what lies ahead for investors.

Listen in!

Related Posts

Latest Post

Leave a Reply

Your email address will not be published. Required fields are marked *